DiaMedica Therapeutics (NASDAQ:DMAC) posted its quarterly earnings results on Tuesday. The company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.07, Morningstar.com reports.

NASDAQ:DMAC traded down $0.86 on Wednesday, reaching $2.60. 9,939 shares of the company’s stock were exchanged, compared to its average volume of 71,483. The company has a quick ratio of 10.49, a current ratio of 10.49 and a debt-to-equity ratio of 0.01. DiaMedica Therapeutics has a 52 week low of $2.46 and a 52 week high of $5.93. The company has a fifty day moving average of $4.00.

In other DiaMedica Therapeutics news, Director Richard D. Pilnik bought 19,000 shares of the business’s stock in a transaction on Friday, May 31st. The stock was purchased at an average price of $2.80 per share, for a total transaction of $53,200.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.80% of the stock is owned by company insiders.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. boosted its position in DiaMedica Therapeutics by 159.7% during the second quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock worth $134,000 after purchasing an additional 16,651 shares during the period. Vanguard Group Inc. bought a new position in DiaMedica Therapeutics during the second quarter worth about $170,000. Eidelman Virant Capital bought a new position in DiaMedica Therapeutics during the second quarter worth about $173,000. Finally, Granite Point Capital Management L.P. bought a new position in DiaMedica Therapeutics during the second quarter worth about $1,141,000. Hedge funds and other institutional investors own 10.69% of the company’s stock.

Several research firms recently weighed in on DMAC. Dougherty & Co began coverage on shares of DiaMedica Therapeutics in a research report on Tuesday, April 30th. They set a “buy” rating and a $8.00 price target for the company. Zacks Investment Research lowered shares of DiaMedica Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. Craig Hallum increased their price target on shares of DiaMedica Therapeutics from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Finally, ValuEngine upgraded shares of DiaMedica Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $8.38.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Recommended Story: Street Name

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.